medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 1

<< Back Next >>

Rev Mex Neuroci 2008; 9 (1)

Vital signs in children exposed to methylphenidate

Reséndiz AJC, Saavedra MY, Rodríguez RE, Yánez AML, Cruz ME, Cruz RQJ

Language: Spanish
References: 13
Page: 14-19
PDF size: 56.18 Kb.


ABSTRACT

Introduction: Methylphenidate (MPH) is one of the most widely used medications to treat Attention Deficit Hyperactivity Disorder (ADHD) in children; its potential side effects have been a permanent concern. Methods: Along a year we surveyed blood pressure, heart rate, cranial circumference, body height and weight of ADHD patients treated with MPH. Individual data were compared with percentile growth charts for age and gender. Results: Fifty six patients were included, ages 4 to 17 years, 82% males. Forty three patients were taking short action MPH and 13 sustained release MPH (OROS). Eighteen patients had ADHD alone and the rest of them had a comorbid ADHD, 16 with epilepsy and 7 had mild mental retardation. Nineteen patients take an antiepileptic drug, 8 a neuroleptic drug and 3 an antidepressive drug. In five patients blood pressure was under normal (3rd centile) without clinical manifestations. Any patient had abnormal heart rates, 15 patients had microcephaly and one had macrocephaly. Four patients had short stature and 3 were above centile 97. Conclusions: We found no significant changes in cardiovascular parameters, patients with low blood pressure were clinically asymptomatic. Weight and height were not affected through the year of follow-up, growth velocity remained normal in all cases. However, we suggest a permanent follow-up in patients under chronic drug treatment.


REFERENCES

  1. Artigas-Pallarés J. Nuevas opciones terapéuticas en el tratamiento del trastorno por déficit de atención/hiperactividad. Rev Neurol 2004; 38(Supl. 1): S117-23.

  2. Thomas D, et al. “Methylphenidate: its pharmacology and uses”. Mayo Clin Proc 2000; 75: 711-21.

  3. Moizeszowicz J. Psicofarmacología psicodinámica IV: estrategias terapéuticas y psiconeurobiológicas. Buenos Aires: Paidós; 2000.

  4. Palumbo D, et al. “Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy”. J Child Adolesc Psychopharmacol 2004; 14(2): 185-94.

  5. Holtkamp K, et al. Methylphenidate-related growth impairment. J Child Adolesc Psychopharmacol 2002 Spring; 12(1): 55-61.

  6. Wilens T, et al. “ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study”. J Am Acad Child Adolesc Psychiatry 2005; 44(10): 1015-23.

  7. Charach A, et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006; 45(4): 415.

  8. Wilens TE, et al. “Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year followup study”. J Clin Psychopharmacol 2004; 24(1): 36-41.

  9. Wilens T, et al. “ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study”. J Am Acad Child Adolesc Psychiatry 2005; 44(10): 1015-23.

  10. Wilens TE, et al. “Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder”. J Clin Psychiatry 2005; 66(2): 253-9.

  11. Rapport MD, et al. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002; 22(8): 1107-31.

  12. Salas AM. Ramírez MJA. Síndromes pediátricos. Fisiopatologia clínica y terapéutica. 3a. Ed. México: Editorial Interamericana; 1987.

  13. Valenzuela RH, Luengas BJ, Marquet SL. Manual de Pediatría. 10a. Ed. México: Editorial Interamericana; 1986.




2020     |     www.medigraphic.com